Other
Adjuvant Chemotherapy
0
Pipeline Programs↗
13
Active Trials↗
2
Companies Involved↗
Adjuvant Chemotherapy is an early-stage landscape with 0 programs across 2 companies. The most active players are Taiho Pharmaceutical Co., Ltd., Central European Cooperative Oncology Group.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
44
clinical trials
Completed15 · 34%
Unknown status11 · 25%
Recruiting9 · 20%
Not yet recruiting3 · 7%
Withdrawn3 · 7%
Terminated2 · 5%
Other1 · 2%
Clinical Trials
Trial Activity
44 trials
Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More
Recruiting·—·Phase 3·NCT06293625·150 enrolled
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2/3·NCT04803539·260 enrolled
Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC
Completed·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT07250360·2,072 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)